E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 3 SEK -3.23% Market Closed
Market Cap: 728.2m SEK

Relative Value

The Relative Value of one ENZY stock under the Base Case scenario is 1.9 SEK. Compared to the current market price of 3 SEK, Enzymatica AB (publ) is Overvalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ENZY Relative Value
Base Case
1.9 SEK
Overvaluation 37%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
38
vs Industry
7
Median 3Y
11.3
Median 5Y
14.5
Industry
2.4
Forward
9.2
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-13.3
Industry
20.3
Forward
-9.8
vs History
vs Industry
Median 3Y
-10.8
Median 5Y
-16
Industry
15.6
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-12.9
Industry
23.1
vs History
80
vs Industry
11
Median 3Y
5.5
Median 5Y
7
Industry
2
vs History
44
vs Industry
7
Median 3Y
11.2
Median 5Y
13.8
Industry
2.5
Forward
8.2
vs History
53
vs Industry
6
Median 3Y
18.3
Median 5Y
22.3
Industry
4.8
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-14.6
Industry
12.5
Forward
-13.1
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-12.9
Industry
15.7
Forward
-12.6
vs History
vs Industry
Median 3Y
-10.7
Median 5Y
-15.5
Industry
14.1
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-15
Industry
17.6
vs History
52
vs Industry
9
Median 3Y
5
Median 5Y
6.1
Industry
1.8

Multiples Across Competitors

ENZY Competitors Multiples
Enzymatica AB (publ) Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Enzymatica AB (publ)
STO:ENZY
728.2m SEK 16 -13.7 -14.1 -12.6
US
Eli Lilly and Co
NYSE:LLY
733.3B USD 15 66.1 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.6B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.7 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
215.9B CHF 3.6 26.1 9.8 11.4
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4 28.3 130.8 197.3
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
199.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
119.6B EUR 1.3 9.4 5.2 6.1
P/E Multiple
Earnings Growth PEG
SE
E
Enzymatica AB (publ)
STO:ENZY
Average P/E: 24.4
Negative Multiple: -13.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.4
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
E
Enzymatica AB (publ)
STO:ENZY
Average EV/EBITDA: 433.3
Negative Multiple: -14.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.8
9%
14.5
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
E
Enzymatica AB (publ)
STO:ENZY
Average EV/EBIT: 1 866.6
Negative Multiple: -12.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.3
21%
9.4
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4